Table 2. Association of clinicopathological features with the diagnosis .
IQR: Interquartile range
*Kruskal-Wallis H test was applied, **Fisher exact/Chi-square test was applied, ***Significant as < 0.05
| Clinicopathological features | Diagnosis | p-value | ||
| Aggressive angiomyxoma | Angiomyofibroblastoma | Cellular angiofibroma | ||
| Age (years) | ||||
| Median (IQR)* | 42.0 (13.5) | 32.0 (13.0) | 28.0 (13.0) | 0.001*** |
| Age groups** | ||||
| ≤30 years, n (%) | 18 (23.4) | 49 (44.1) | 13 (68.4) | 0.003*** |
| 31-45 years, n (%) | 40 (51.9) | 43 (38.7) | 4 (21.1) | |
| >45 years, n (%) | 19 (24.7) | 19 (17.1) | 2 (10.5) | |
| Tumor size (cm) | ||||
| Median (IQR)* | 7.0 (7.00) | 4.0 (3.00) | 2.0 (1.7) | <0.001*** |
| Tumor size groups** | ||||
| <5 cm, n (%) | 20 (26) | 59 (53.2) | 19 (100) | <0.001*** |
| 6-10 cm, n (%) | 36 (46.8) | 42 (37.8) | 0 (0) | |
| >10 cm, n (%) | 21 (27.3) | 10 (9) | 0 (0) | |
| Follow-up duration (years), median (IQR)* | 8.0 (4.0) | 7.0 (6.0) | 8.0 (5.0) | 0.193 |
| Tumor Site** | ||||
| Labia majora, n (%) | 16 (20.8) | 36 (32.4) | 0 (0) | <0.001*** |
| Vagina, n (%) | 19 (24.7) | 37 (33.3) | 1 (5.3) | |
| Vulva, n (%) | 42 (54.5) | 38 (34.2) | 18 (94.7) | |
| Histological findings | ||||
| Lesional cells | ||||
| Spindle** | ||||
| Yes, n (%) | 77 (100) | 25 (22.5) | 19 (100) | <0.001*** |
| No, n (%) | 0 (0) | 86 (77.5) | 0 (0) | |
| Epithelioid** | ||||
| Yes, n (%) | 10 (13) | 95 (85.6) | 3 (15.8) | <0.001*** |
| No, n (%) | 67 (87) | 16 (14.4) | 16 (84.2) | |
| Stroma | ||||
| Myxoid stroma** | ||||
| Yes, n (%) | 71 (92.2) | 12 (10.8) | 2 (10.5) | <0.001*** |
| No, n (%) | 6 (7.8) | 99 (89.2) | 17 (89.5) | |
| Collagenized stroma** | ||||
| Yes, n (%) | 31 (40.3) | 89 (80.2) | 11 (57.9) | <0.001*** |
| No, n (%) | 46 (59.7) | 22 (19.8) | 8 (42.1) | |
| Hyalinized stroma** | ||||
| Yes, n (%) | 17 (22.1) | 33 (29.7) | 16 (84.2) | <0.001*** |
| No, n (%) | 60 (77.9) | 78 (70.3) | 3 (15.8) | |
| Stromal smooth muscles** | ||||
| Yes, n (%) | 33 (42.9) | 11 (9.9) | 2 (10.5) | <0.001*** |
| No, n (%) | 44 (57.1) | 100 (90.1) | 17 (89.5) | |
| Vasculature | ||||
| Thickened muscular vessels** | ||||
| Yes, n (%) | 61 (79.2) | 23 (20.7) | 2 (10.5) | <0.001*** |
| No, n (%) | 16 (20.8) | 88 (79.3) | 17 (89.5) | |
| Hyalinized vessels** | ||||
| Yes, n (%) | 42 (54.5) | 48 (43.2) | 15 (78.9) | 0.011*** |
| No, n (%) | 35 (45.5) | 63 (56.8) | 4 (21.1) | |
| Borders** | ||||
| Ill-defined, n (%) | 60 (77.9) | 12 (10.8) | 16 (84.2) | <0.001*** |
| Well defined, n (%) | 17 (22.1) | 99 (89.2) | 3 (15.8) | |
| Immunochemical findings | ||||
| Smooth muscle actin** | ||||
| Positive, n (%) | 34 (44.2) | 69 (62.2) | 9 (47.4) | 0.042*** |
| Negative, n (%) | 43 (55.8) | 42 ( 37.8) | 10 (52.6) | |
| Vimentin** | ||||
| Positive, n (%) | 72 (93.5) | 103 (92.8) | 16 (84.2) | 0.360 |
| Negative, n (%) | 5 (6.5) | 8 (7.2) | 3 (15.8) | |
| Desmin** | ||||
| Positive, n (%) | 19 (24.7) | 38 (34.2) | 1 (5.3) | 0.024*** |
| Negative, n (%) | 58 (75.3) | 73 (65.8) | 18 (94.7) | |
| Recurrence** | ||||
| Yes, n (%) | 21 (27.3) | 8 (7.2) | 1 (5.3) | <0.001*** |
| No, n (%) | 56 (72.7) | 103 (92.8) | 18 (94.7) | |